BrightPath Biotherapeutics Co., Ltd. (TYO:4594)
Japan · Delayed Price · Currency is JPY 51.00
-1.00 (-1.92%)
Jul 16, 2026, 10:13 AM JST
TYO:4594 Revenue
In the fiscal year ending March 31, 2026, BrightPath Biotherapeutics had annual revenue of 84.00K JPY, down -92.59%. BrightPath Biotherapeutics had revenue of 51.00K in the quarter ending March 31, 2026, a decrease of -95.11%.
Revenue
84.00K
Revenue Growth
-92.59%
P/S Ratio
85,980.28
Revenue / Employee
2.00K
Employees
42
Market Cap
7.22B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 84.00K | -1.05M | -92.59% |
| Mar 31, 2025 | 1.13M | 1.06M | 1,473.61% |
| Mar 31, 2024 | 72.00K | -353.93M | -99.98% |
| Mar 31, 2018 | 354.00M | -175.00M | -33.08% |
| Mar 31, 2017 | 529.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.59B |
| CellSource | 3.67B |
| StemCell Institute | 2.81B |
| MEDINET | 998.00M |
| OncoTherapy Science | 808.00M |
| PRISM BioLab Co.,LTD | 711.65M |
| Carna Biosciences | 619.35M |
| Chiome Bioscience | 601.75M |